Processa Pharmaceuticals (PCSA) Change in Receivables (2012 - 2016)
Processa Pharmaceuticals' (PCSA) quarterly Change in Receivables came in at -$25000.0 in Q1 2016, up 71.0% on a YoY basis from -$14619.7 in Q2 2015, and down 2008.4% quarter-over-quarter from $1310.0 in Q4 2015.
Powered by 
Analysis
Processa Pharmaceuticals (PCSA) Change in Receivables (2012 - 2016) Analysis & Trends
Processa Pharmaceuticals (PCSA) has reported Change in Receivables for 5 consecutive years, with -$25000.0 the latest figure, recorded in Q1 2016.
- For the quarter ending Q1 2016, Change in Receivables rose 71.0% year-over-year to -$25000.0; the trailing twelve-month figure through Jun 2016 stood at $59925.0 (up 569.03% YoY), and the FY2015 full-year result was -$3838.0, down 121.45% from the prior year.
- Change in Receivables slipped to -$25000.0 in Q1 2016 per PCSA's latest filing, from $1310.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $83615.0 in Q3 2015 and bottomed at -$86214.0 in Q1 2015.
- Historically, Change in Receivables has averaged $370.07 across 5 years, with a median of $1310.0 in 2015.
- The sharpest annual moves came in 2014 and 2015: Change in Receivables soared 389.11% in 2014, then sank 7429.61% in 2015.
- Over 5 years, Change in Receivables stood at -$30451.0 in 2012, then jumped by 117.07% to $5199.0 in 2013, then jumped by 389.11% to $25429.0 in 2014, then tumbled by 94.85% to $1310.0 in 2015, then sank by 2008.4% to -$25000.0 in 2016.
- According to Business Quant data, Change in Receivables over the past three periods registered -$25000.0, $1310.0, and $83615.0 for Q1 2016, Q4 2015, and Q3 2015 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 1.35 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 1.37 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | - |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | - |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 73.80 Mn |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | -1.70 Mn |
| 10 | Processa Pharmaceuticals | 5.75 Mn | 5.75 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2016 | -25,000.00 |
| Dec 31, 2015 | 1,310.00 |
| Sep 30, 2015 | 83,615.00 |
| Jun 30, 2015 | -2,549.00 |
| Mar 31, 2015 | -86,214.00 |
| Dec 31, 2014 | 25,429.00 |
| Sep 30, 2014 | 72,291.00 |
| Jun 30, 2014 | -78,685.00 |
| Mar 31, 2014 | -1,145.00 |
| Dec 31, 2013 | 5,199.00 |
| Sep 30, 2013 | 36,755.00 |
| Jun 30, 2013 | -41,454.00 |
| Mar 31, 2013 | 11,251.00 |
| Dec 31, 2012 | -30,451.00 |
| Sep 30, 2012 | 35,199.00 |